StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
11
Publishing Date
2024 - 03 - 04
14
2023 - 12 - 21
13
2023 - 12 - 12
13
2023 - 12 - 06
13
2023 - 10 - 18
12
2023 - 10 - 16
16
2023 - 10 - 04
14
2023 - 09 - 26
17
2023 - 09 - 20
12
2023 - 09 - 07
13
2023 - 06 - 26
13
2023 - 04 - 25
15
2023 - 04 - 17
14
2023 - 02 - 23
13
2023 - 01 - 30
16
2023 - 01 - 25
13
2022 - 10 - 12
13
2022 - 08 - 22
13
2022 - 06 - 09
11
2022 - 06 - 06
11
2022 - 05 - 24
11
2022 - 05 - 17
13
2022 - 05 - 03
12
2022 - 05 - 02
11
2022 - 03 - 28
14
2022 - 01 - 24
18
2022 - 01 - 20
11
2022 - 01 - 18
11
2021 - 12 - 22
12
2021 - 12 - 21
11
2021 - 12 - 13
15
2021 - 12 - 09
12
2021 - 12 - 06
13
2021 - 11 - 29
11
2021 - 11 - 12
11
2021 - 11 - 01
12
2021 - 10 - 25
11
2021 - 10 - 19
11
2021 - 10 - 18
15
2021 - 10 - 14
12
2021 - 10 - 12
12
2021 - 10 - 07
12
2021 - 10 - 04
12
2021 - 09 - 30
11
2021 - 09 - 09
11
2021 - 09 - 07
12
2021 - 08 - 24
11
2021 - 06 - 29
12
2021 - 06 - 28
11
2021 - 06 - 25
13
2021 - 06 - 23
14
2021 - 06 - 21
13
2021 - 06 - 11
11
2021 - 06 - 04
13
2021 - 06 - 03
12
2021 - 06 - 01
14
2021 - 05 - 21
15
2021 - 05 - 03
14
2021 - 04 - 14
11
2021 - 03 - 22
13
Sector
Health technology
11
Tags
5g
6
Acquisition
11
Application
10
Approval
4
Authorized
3
Biopharma
5
Biotech-beach
4
Biotechnology
3
Blood
4
Brands
3
Cancer
4
China
4
Clinical-trials-phase-ii
5
Clinical-trials-phase-iii
3
Commercialization
4
Communication
3
Communications
3
Conference
21
Covid
6
Covid-19
5
Designation
4
Device
3
Diabetes
4
Drug
3
Energy
6
Europe
7
Ev
6
Events
6
Fda
6
Food
14
Growth
15
Insulin
4
Iot
5
License
4
Life science
4
Liver
10
Market
6
Merge
5
Money
16
N/a
338
Nasdaq
4
Offering
20
Partnership
4
Pharma
5
Pharmaceutical
7
Phase 1
7
Phase 2
11
Phase 3
9
Positive
7
Presentation
6
Program
5
Publication
6
Research
16
Results
16
Solar
4
Technology
7
Therapeutics
6
Therapy
6
Treatment
11
Trial
22
Entities
Adamis pharmaceuticals corporation
1
Agios pharmaceuticals, inc.
1
Amgen inc.
1
Anavex life sciences corp.
1
Antares pharma, inc.
1
Crinetics pharmaceuticals, inc.
2
Eli lilly and company
1
Entera bio ltd.
1
Hoth therapeutics, inc.
1
Rockwell medical, inc.
1
Syndax pharmaceuticals, inc.
1
Symbols
ADMP
1
AGIO
1
AMGN
1
ATRS
1
AVXL
1
CRNX
2
ENTX
1
HOTH
1
LLY
1
RMTI
1
SNDX
1
Exchanges
Nasdaq
10
Nyse
1
Crawled Date
2021 - 06 - 28
11
Crawled Time
06:00
1
12:00
7
13:15
1
17:00
1
20:00
1
Source
ir.hoththerapeutics.com
1
www.anavex.com
1
www.biospace.com
5
www.crinetics.com
1
www.globenewswire.com
2
www.prnewswire.com
1
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
publishing date :
2021 - 06 - 28
tags :
Treatment
save search
Entera Bio to Conduct Conference Call on June 30 to Discuss Phase 2 Results for EB613 Positioned to be the First Oral Bone-Building Agent for the Treatment of Osteoporosis
Published:
2021-06-28
(Crawled : 20:00)
- globenewswire.com
ENTX
|
$2.03
-0.98%
36K
|
Health Technology
|
-66.23%
|
O:
-0.66%
H:
0.36%
C:
-4.15%
AMGN
|
News
|
$273.38
0.54%
790K
|
Health Technology
|
11.97%
|
O:
0.16%
H:
0.3%
C:
-0.31%
treatment
phase 2
bone
phase 2 results
results
eb613
conference
osteoporosis
SLE-UPDATE Study Finds Reducing Pain, Fatigue, and Flares are Top Treatment Goals for People with Lupus
Published:
2021-06-28
(Crawled : 17:00)
- prnewswire.com
LLY
|
News
|
$742.04
1.46%
540K
|
Health Technology
|
217.67%
|
O:
-0.53%
H:
0.38%
C:
-0.34%
treatment
lupus
Crinetics Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
Published:
2021-06-28
(Crawled : 13:15)
- crinetics.com
CRNX
G
|
$44.245
1.85%
150K
|
Health Technology
|
121.41%
|
O:
1.53%
H:
1.41%
C:
-1.2%
treatment
phase 3
Hoth Therapeutics Announces Positive Safety Results from AD001 Cohort 1 of Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis
Published:
2021-06-28
(Crawled : 12:00)
- ir.hoththerapeutics.com
HOTH
|
$1.15
11K
|
Health Technology
|
-27.67%
|
O:
1.26%
H:
4.97%
C:
-1.86%
treatment
phase 1
positive
results
dermatitis
trial
atopic dermatitis
phase 1b
al001
adi-001
phase 2b
SNDX-5613 Granted FDA Fast Track Designation for the Treatment of Relapsed/Refractory Acute Leukemias
Published:
2021-06-28
(Crawled : 12:00)
- biospace.com/
SNDX
|
$21.19
1.1%
200K
|
Health Technology
|
14.16%
|
O:
4.25%
H:
2.09%
C:
-5.49%
treatment
fda
fda fast track
fast track
leukemia
fast track designation
granted
grant
designation
Crinetics Pharmaceuticals Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
Published:
2021-06-28
(Crawled : 12:00)
- biospace.com/
CRNX
G
|
$44.245
1.85%
150K
|
Health Technology
|
121.41%
|
O:
1.53%
H:
1.41%
C:
-1.2%
treatment
phase 3
Agios Submits Marketing Authorisation Application to European Medicines Agency for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
Published:
2021-06-28
(Crawled : 12:00)
- biospace.com/
AGIO
|
$31.645
4.75%
350K
|
Health Technology
|
-46.74%
|
O:
1.32%
H:
0.35%
C:
-2.4%
treatment
europe
application
Rockwell Medical, Inc. Files Pre-IND Meeting Request with FDA for its Proposed Clinical Trial of FPC as a Treatment for Iron Deficiency Anemia in Patients Receiving Home Infusion
Published:
2021-06-28
(Crawled : 12:00)
- biospace.com/
RMTI
|
$1.53
0.99%
15K
|
Health Technology
|
65.55%
|
O:
3.06%
H:
4.26%
C:
2.14%
treatment
fda
iron deficiency
anemia
trial
Adamis Sends Letter to Stockholders Regarding Its Strategic Focus on Tempol as a Potentially Potent Treatment for COVID-19
Published:
2021-06-28
(Crawled : 12:00)
- biospace.com/
ADMP
|
$0.7751
0.86%
2.6%
120K
|
Health Technology
|
-36.98%
|
O:
0.81%
H:
3.23%
C:
-3.23%
covid
treatment
potential
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy Endpoints with Significant Biomarker Correlation in Placebo-Controlled Phase 2 Clinical Trial for the Treatment of Patients with Parkinson’s Disease Dementia
Published:
2021-06-28
(Crawled : 12:00)
- anavex.com
AVXL
|
$3.75
1.9%
650K
|
Health Technology
|
-85.13%
|
O:
20.0%
H:
6.06%
C:
-2.83%
disease
treatment
phase 2
dementia
correlation
parkinson
life science
trial
anavex®2-73
anavex
biomarkers
Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction
Published:
2021-06-28
(Crawled : 06:00)
- globenewswire.com
ATRS
|
$5.59
0.0%
|
Health Technology
|
28.8%
|
O:
0.23%
H:
1.84%
C:
-1.61%
treatment
phase 3
Gainers vs Losers
87%
13%
Top 10 Gainers
MTTR
|
News
M
|
$4.595
164.08%
13M
|
AGBA
|
$2.61
108.8%
41M
|
Finance
CZOO
|
$9.32
86.77%
18M
|
EDBL
|
News
|
$6.7
78.19%
1.7M
|
MTC
|
$2.28
46.15%
2.6M
|
Technology Services
OPRT
|
News
|
$3.14
39.56%
7.6M
|
Finance
VNRX
|
$0.8
33.33%
2.9M
|
Health Technology
MLEC
|
$1.865
33.21%
2.4M
|
n/a
PALI
|
$6.37
29.21%
21M
|
Manufacturing
LOCL
|
$3.33
27.59%
43K
|
Your saved searches
Save your searches and get alerts when important news are released.